Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-10-01 Regulatory Filings
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 30, 2024, reporting the completion of a significant transaction: the sale of Seres Therapeutics' VOWST microbiome therapeutic business to Société des Produits Nestlé S.A. The filing details multiple agreements related to the transaction, including a Transition Services Agreement, Cross-License Agreement, Securities Purchase Agreement, Employee Support Agreement, and termination of a Credit Agreement. The document is a current report on material definitive agreements and completion of asset disposition, typical content for an 8-K filing. It is not an annual or quarterly report, earnings release, or other financial statement. It is a regulatory announcement of a material event and related agreements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2024-10-01 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 26, 2024. It reports the submission of matters to a vote of security holders at a special meeting, specifically the approval of a transaction involving the sale of a business unit. The document details voting results on proposals related to the transaction and adjournment. It does not contain full financial statements or detailed financial analysis but rather the official voting results from a shareholder meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is 5630 characters, sufficient to include detailed voting results, not just a brief announcement. Therefore, the correct classification is DVA with high confidence.
2024-09-26 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes detailed disclosures related to a proxy solicitation for a stockholder meeting, including information about a proposed transaction, solicitation participants, and forward-looking statements. The document references a definitive proxy statement and additional materials related to the solicitation of proxies for a stockholder vote. This type of filing is specifically categorized as Remuneration Information (DEF 14A) when it details compensation, but here it is a proxy statement related to a transaction and solicitation, which fits the Proxy Solicitation & Information Statement (PSI) category. The document is not an annual report, earnings release, or other financial report, but a proxy statement filing. Therefore, the correct classification is PSI with high confidence.
2024-09-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by Seres Therapeutics, Inc. It reports on recent events including the posting of a slide presentation and press release about clinical study results (SER-155 Phase 1b Cohort 2 Study) and an updated corporate presentation. The document includes detailed clinical study results and corporate strategy discussion but is primarily an event-driven disclosure rather than a full financial report. The document also references exhibits containing presentations and press releases, which are typical for Regulation FD disclosures. The Form 8-K is a current report used to announce material events and updates, not a full annual or quarterly report. The content does not contain comprehensive financial statements or detailed management discussion and analysis that would classify it as an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement, audit report, or earnings release. The primary purpose is to disclose clinical study results and corporate updates in a current report format. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories.
2024-09-12 English
DEFM14A Filing
Regulatory Filings
2024-08-26 English
4
Director's Dealing
2024-08-19 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.